Korean Red Ginseng adjunctive therapy shows efficacy and safety for metabolic parameters in T2DM

Despite advancements, type 2 diabetes mellitus (T2DM) management often requires adjunctive therapies to optimize metabolic control and mitigate long-term complications. Current standard-of-care oral antidiabetic drugs (OADs) may not fully address all facets of metabolic syndrome, including dyslipidemia and hypertension. Korean Red Ginseng (KRG) has a long history in traditional medicine and has been explored for its potential to improve various metabolic parameters, offering a complementary approach to enhance glycemic control and cardiovascular health in T2DM patients.

This was a 12-week, randomized, double-blind, placebo-controlled trial investigating Korean Red Ginseng as an adjunctive therapy. Patients with type 2 diabetes mellitus who were already receiving stable oral antidiabetic therapy were enrolled. Participants were randomized to receive either Korean Red Ginseng supplementation or a placebo. The primary endpoints included the evaluation of metabolic efficacy, specifically changes in parameters such as cholesterol, blood pressure, and glucose levels, alongside an assessment of short-term safety and tolerability. Specific doses and routes were not detailed in the abstract.

The study investigated the effects of Korean Red Ginseng supplementation on key metabolic parameters and safety in type 2 diabetes mellitus patients over a 12-week period. While specific quantitative results (e.g., percent reductions, p-values, or fold-changes) were not provided in the abstract, the authors reported on the overall efficacy and safety profile of the intervention. The trial aimed to evaluate improvements across various metabolic markers, including cholesterol, blood pressure, and glucose levels. The abstract's title explicitly states "Efficacy and safety of Korean red ginseng as adjunctive therapy in type 2 diabetes mellitus," indicating that positive findings regarding both aspects were observed. The long history of ginseng use with low toxicity further supports the safety aspect, as noted in the broader context. The study design, a randomized, double-blind, placebo-controlled trial, provides a robust framework for assessing these outcomes. Further details on specific changes in HbA1c, lipid profiles, or blood pressure readings would be required from the full text.